Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting
SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently completed Phase 2 clinical development with potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
The presentations are as follows:
Saturday, May 16th
Oral Presentation - Lecture Hall 3a (14:54 - 15:06)
Sunday, May 17th
Poster Presentations - New antimicrobials against Gram-positives (13:30 - 14:30)
Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company’s lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius’ pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.
CONTACT: Jason Spark of Porter Novelli Life Sciences, +1-619-849-6005,
jspark@pnlifesciences.com, for Trius Therapeutics, Inc.
Web site: http://www.triusrx.com/
